Five companies are carrying out 63% of the most urgently needed R&D projects
Majority of key on-patent products have access initiatives, but these are limited in reach
Access initiatives for cancer products focus on pricing, mainly for small populations
Priority R&D: are the most urgently needed new products being developed?
On-patent products: how do pharmaceutical companies use pricing, licensing and donations to improve access to key medicines?
View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.